Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
about
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib
P2860
Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Imatinib mesylate in Philadelp ...... r failure of interferon alpha.
@ast
Imatinib mesylate in Philadelp ...... r failure of interferon alpha.
@en
type
label
Imatinib mesylate in Philadelp ...... r failure of interferon alpha.
@ast
Imatinib mesylate in Philadelp ...... r failure of interferon alpha.
@en
prefLabel
Imatinib mesylate in Philadelp ...... r failure of interferon alpha.
@ast
Imatinib mesylate in Philadelp ...... r failure of interferon alpha.
@en
P2093
P1433
P1476
Imatinib mesylate in Philadelp ...... er failure of interferon alpha
@en
P2093
P577
2005-01-01T00:00:00Z